. 2019 Dec 17;7:353. doi: 10.1186/s40425-019-0771-1

Table 5.

Subgroup analysis of efficacy and safety according to tumor type and ICI therapy

Tumor Types (N)	Co-infection (N)	Anti-PD-(L)1 Monotherapy			Anti-PD-(L)1 plus Chemotherapy
Tumor Types (N)	Co-infection (N)	ORR^a N (%)	Any grade irAEs N (%)	Grade ≥ 3 irAEs N (%)	ORR N (%)	Any grade irAEs N (%)	Grade ≥ 3 irAEs N (%)
NSCLC (22)	HIV (12)	1(13)	2(25)	2(25)	3(75)	1(25)	0
NSCLC (22)	HBV/HCV(10)	1(14)	4(57)	2(29)	2(67)	1(33)	1(33)
HCC (17)	HBV/HCV(16)	3(19)	7(44) ^b	4(25)^b

^aResponse evaluable patients

^bTwo patients with baseline grade ≥ 2 hepatitis